Pfizer (PFE) Tops Q3 EPS by 21c, Misses on Revenue; Offers FY25 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $28.45 -1.25%
EPS Growth %: -12.6%
Financial Fact:
Discontinued operations--net of tax (in dollars per share): 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -12.6%
Financial Fact:
Discontinued operations--net of tax (in dollars per share): 0
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q3 EPS of $0.87, $0.21 better than the analyst estimate of $0.66. Revenue for the quarter came in at $16.7 billion versus the consensus estimate of $16.8 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $3.00-$3.15, versus the consensus of $3.04. Pfizer sees FY2025 revenue of $61-64 billion, versus the consensus of $62.8 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- BofA Securities Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Neutral
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
